Abstract The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying
the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain …

The cholinergic hypothesis of decline in dementia, whereby deficits in learning, memory and
behavior are caused, at least in part, by decreased levels of acetylcholine (ACh) in the brain …

Background: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's
disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and …

Background Alzheimer's disease (AD) is a neurodegenerative disorder that affects over 45
million people worldwide. Patients with severe AD require help with daily activities and show …

The dysfunction and loss of basal forebrain cholinergic neurons and their cortical projections
are among the earliest pathological events in the pathogenesis of Alzheimer's disease (AD) …

This review considers the role of drug therapy in the treatment of post-stroke aphasia, the
evidence for efficacy of different agents, and the theory-based explanations of drug-related …

Intracerebroventricular (ICV) injection of streptozotocin (STZ) causes cognitive impairment in
rats. ICV STZ is known to impair cholinergic neurotransmission by decreasing choline …

Background There is an association between Alzheimer disease and sleep-disordered
breathing. Donepezil is the drug most frequently used to treat cognitive symptoms in …

Donepezil and rivastigmine are acetylcholinesterase (AChE) inhibitors used to improve
cholinergic neurotransmission and cognitive function in Alzheimer's disease (AD). This study …

Drug-target residence time (t= 1/k off, where k off is the dissociation rate constant) has
become an important index in discovering better-or best-in-class drugs. However, little effort …